MetaCap

Compass Therapeutics Inc. (CMPX)

NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.6882+0.0097 (+1.43%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CMPX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$123.94M
EPS (TTM)
-$0.46
52-week range
0.57 – 6.88
Day range
0.6405 – 0.7297
Volume / Avg
1.82M / 3.88M
Beta
—

52-week range

$0.57$6.88

CMPX stock today

Compass Therapeutics (CMPX) closed at $0.6882 on Nov 20, up 1.43% (+$0.0097), versus the S&P 500's 3.70% decline. Trading was light, with 1.82M shares changing hands, about 47% of the average daily volume. At this level, CMPX sits near the bottom of its 52-week range of $0.57 to $6.88: 90.0% below the high, set on Feb 3, 2026 and 20.7% above the low.

CMPX is down 87.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.9%. Compass Therapeutics has posted a net loss over the last twelve months (EPS of -$0.46), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Compass Therapeutics

Company profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Thomas J. Schuetz M.D., Ph.D.
Headquarters
Boston, MA
Employees
39

Financial highlights

Full financials

In fiscal 2025, Compass Therapeutics generated $0 in revenue, down 100.0% from fiscal 2024, the first decline in the 9 years shown. Compass Therapeutics reported a net loss of $66.5 million, compared with a loss of $49.4 million a year earlier.

Compass Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$850.00K$0——
Growth-100.00%————
Net income$-66.49M$-49.38M$-42.49M$-39.23M$-82.18M
EPS (diluted)————$-1.31

Analyst forecast

Forecast

Consensus (15 analysts)

buy

Avg. price target

$5.26+664.31%

  • Strong buy 2
  • Buy 10
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $0.90High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.15 vs $-0.12
Surprise
-25.00%

CMPX news

All CMPX news

Compass Therapeutics peers

Health Care sector
CMPX peer companies
CompanyPrice% ChgMarket capCompare
IVVDInvivyd Inc.0.4127-7.45%$122.01Mvs CMPX
HUMAHumacyte Inc.0.4454-17.90%$123.73Mvs CMPX
ENGNenGene Therapeutics Inc.1.74-1.14%$116.61Mvs CMPX
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs CMPX
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs CMPX
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs CMPX
TARAProtara Therapeutics Inc.2.28-5.00%$140.38Mvs CMPX
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs CMPX

Indexes, lists and sector

Compass Therapeutics stock FAQ

What is Compass Therapeutics's stock price today?

CMPX last traded at $0.6882 as of Nov 20, 4:00 PM EST, up 1.43% on the day. Prices are delayed at least 15 minutes.

Who is Compass Therapeutics's CEO?

Dr. Thomas J. Schuetz M.D., Ph.D. is the chief executive officer of Compass Therapeutics Inc., which has about 39 employees.

What is the CMPX 52-week high?

The 52-week high for CMPX is $6.88 and the 52-week low is $0.57. The stock is currently 90.0% below its high.

Compare CMPX